Introduction {#sec1-1}
============

Coronavirus disease (COVID-19) occurs due to the severe acute eespiratory syndrome coronavirus-2 virus (SARS-CoV-2). This virus is a new member of the β coronavirus family, which also has the other offenders of previous coronavirus outbreaks namely, SARS-CoV and MERS-CoV.\[[@ref1]\] Initially started as a result of zoonotic spillover, the further spread of the SARS-CoV-2 virus is the result of human to human community transmission, the majority through droplets and direct contact. Despite low mortality (2%--3%) of COVID-19 as compared to the MERS (35%--40%) and SARS outbreak (9%--10%), the total disease burden has outnumbered the previous coronavirus outbreaks by humongous margins \[Link for up to date information: <https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>\]\[[Figure 1](#F1){ref-type="fig"}\].

![No of COVID-19 cases in top 10 nations with breakdown of details in confirmed, recovered and died cases](JFMPC-9-1784-g001){#F1}

Facts and Figures of COVID-19 Disease Burden in United States {#sec1-2}
=============================================================

The number of known COVID-19 cases in the United States (US) is rising exponentially \[[Figure 2](#F2){ref-type="fig"}\]. As of 31^st^ March 2020, there are at least 211,408 confirmed COVID-19 cases with 4,718 deaths, involving every U.S. state, plus Washington, D.C., and the three U.S. territories.\[[@ref2]\] For most of the cases, the reason of how the virus was contracted is not clear \[Link for upto date information: *<https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html>*\]\[[Table 1](#T1){ref-type="table"}\]. The number of new cases took a gigantic surge around the last week of March, and since then it has been up-trending \[Link for up to date information: *<https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html#2019coronavirus-summary>*\]\[[Figure 3](#F3){ref-type="fig"}\].
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###### 

Breakdown of the possible reasons of how SARS-CoV-2 Virus Was Contracted in U.S.

  (Top 20 reasons)                                                  Cases
  ----------------------------------------------------------------- -------
  Travel overseas                                                   176
  Travel within the U.S.                                            168
  Life Care nursing facility; Kirkland, Wash.                       129
  Community in New Rochelle, N.Y.                                   119
  Gallatin Center for Rehabilitation and Healing; Gallatin, Tenn.   115
  Cook County Jail; Chicago                                         113
  Biogen conference in Boston                                       109
  Pleasant View Nursing Home; Mount Airy, Md.                       77
  Aboard the U.S.S. Theodore Roosevelt; Guam                        70
  Cedar Mountain Post-Acute Care Facility; Yucaipa, Calif.          57
  Travel in Egypt                                                   52
  Careage of Whidbey; Coupeville, Wash.                             44
  Diamond Princess cruise ship                                      43
  Long-term care facility; DuPage County, Ill.                      42
  Lambeth House senior living facility; New Orleans                 42
  Travel in Italy                                                   39
  First Assembly of God; Greers Ferry, Ark.                         37
  Shuksan Healthcare Center; Bellingham, Wash.                      32
  Family of Caring nursing home; Montclair, N.J.                    30
  St. Joseph's Senior Nursing Home; Woodbridge, N.J.                29

Data adapted from <https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html> (Updated till 03.31.20)
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The first case of the U.S. was confirmed in a 35-year-old male from Snohomish County, Washington on 20^th^ January 2020. He had a travel history to Wuhan, China and had been symptomatic for 4 days with upper respiratory tract symptoms before presenting to the emergency room. Nasopharyngeal and oropharyngeal swabs were collected, which came back positive for SARS-CoV-2 by real-time reverse-transcriptase--polymerase-chain-reaction (rRT-PCR) assay. Very soon, on 30^th^ January 2020, the first COVID-19 case resulting from a person to person transmission within the U.S. without any travel history was detected in a 54-year-old male from Chicago, Illinois.\[[@ref3]\] This tightened the scrutiny nationwide to look for more COVID-19 suspects that led to the more detection and isolation of confirmed cases. As this pandemic is a rapidly evolving scenario, and new data are constantly pouring in, we recommended readers to refer to link provided above to ensure they are up-to-date with latest information or facts. There are many reports of cluster detection throughout the U.S., but the following are examples of different case scenarios reported from three different states, which confirm that COVID-19 is now a nationwide problem.

Nursing home tragedy, Kirkland, Washington {#sec2-1}
------------------------------------------

Unfortunately, just like in the other parts of the world, the U.S. is also having more fatalities amongst the older population, individuals with medical comorbidities and friable sick residents of old age homes and nursing facilities. Lifecare Nursing facility in Kirkland, Washington is a classic example of the catastrophe that costed the life of the COVID-19 struck 59 elderly residents. Similar reports are pouring in from many other nursing homes and rehabilitation centers nationwide. Considering the high risk of acquiring the SAR-CoV-2 infection, the Centers for Disease Control and Prevention (CDC) has issued interim guidance with advice to all nursing homes, hospitals, and rehabilitation centers to try to limit all visitors, and non essential personnel barring an end-of-life situation.

Synagogue tragedy, New Rochelle, New York {#sec2-2}
-----------------------------------------

Another unfortunate incident happened in New Rochelle, New York at a synagogue where there was a mass community transmission of SAR-CoV-2 virus during a local prayer gathering. The incident came into notice after the first case detection on 3^rd^ March 2020. Soon, more than 100 confirmed COVID-19 cases have been reported in individuals who were either directly or indirectly associated with that synagogue. This led to an emergent situation and in order to halt further transmission, a prompt decision was made to create a 1-mile "containment area" around the synagogue, which was considered as an epicenter of COVID-19 outbreak in New Rochelle. Currently, New York has the greatest number of COVID-19 cases than any other states combined together.

Cruise ships tragedy (Diamond Princess, and Grand Princess) {#sec2-3}
-----------------------------------------------------------

Cruise ships have always been known for outbreaks related to various infectious diseases in the past. This fear came to reality during this pandemic as well. The first incident was related with the Diamond Princess cruise ship which was docked at Yokohama port, Japan with more than 3,700 people on board for the concerns of COVID-19 outbreak. Japan government ordered for a quarantine of the cruise ship and its occupants at port itself with an immediate effect from 5^th^ February 2020 for 2 weeks. On 17^th^ February 2020, the U.S. finally evacuated its 300 Americans from the cruise ship. Since then, similar incidents of COVID-19 positive cases have been reported in other cruise ships as well for instance- Caribbean Princess and California Princess ship.

Role of Centers for Disease Control and Prevention (CDC) {#sec1-3}
========================================================

COVID-19 pandemic is a rapidly evolving situation. CDC is the U.S.\'s health protection agency, committed to save lives and protect its people from health threats.\[[@ref4]\] CDC is constantly monitoring COVID-19 pandemic and providing interim guidance to the public health authorities, hospitals, schools, aviation, and homeland security department and other partners that come in the U.S. jurisdictions \[[Figure 4](#F4){ref-type="fig"}\]. The CDC\'s Epidemic Intelligence Service (EIS) officials have so far done a commendable job in their attempt to identify the community transmission, i.e. the source of the COVID-19 cases clusters and rapidly implementing the adequate control measures. On 12^th^ March 2020, CDC recommended considering postponing or canceling any mass gathering to contain community transmission and discouraged handshakes and high fives. Similarly, the CDC recommended to implement social distancing and avoid gatherings of more than 10 at public places.

![Detailed outline of the role of Centers for Disease Control and Prevention (CDC)](JFMPC-9-1784-g004){#F4}

COVID-19 Pandemic: A National Emergency Situation {#sec1-4}
=================================================

Considering the worsening situation, the U.S. government recently declared COVID-19 pandemic as a national emergency on 13^th^ March 2020. The government also signed an \$8.3 billion emergency spending bill on 6^th^ March 2020 to be used in various sectors. As of now, the proposal aims to direct the funds (approximate numbers) towards the research and development of vaccines (\$3 billion); in public health funding (\$2.2 billion); to aid coronavirus struck countries overseas (\$1.25 billion); towards medical supplies, health-care preparedness (\$1 billion). Numerically, this is more than the amount released during the previous epidemics \[\$5.4 billion during the Ebola outbreak (2014) and \$7 billion during the H1N1 outbreak (2009)\]. The following are the other major decisions and actions being taken by the U.S. authorities in order to tackle the COVID-19 pandemic and its consequences \[[Figure 5](#F5){ref-type="fig"}\]. As the numbers are rising every day and economic slowdown has already hit rock-bottom, the U.S. administration is also considering releasing another stimulus package, which could worth anywhere from \$850 billion to more than \$1 trillion in order to battle the economic crisis.
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Recognizing the power of Telemedicine during COVID-19 crisis {#sec2-4}
------------------------------------------------------------

In the U.S., telemedicine services have always played an important component in health care. From making an appointment to discussing the lab results with health care providers via the patient portal, telemedicine has always been considered as a backbone of the U.S. health care system. Now with COVID-19 pandemic, its importance has been felt more than ever. Many hospitals acknowledged concerns over the enormous volumes of patients trying to consult doctors about their symptoms. Considering this unprecedented tele query loads, many state\'s individual medical societies approached to the U.S.\'s Board of Registration in Medicine and requested greater flexibility and clarification regarding the health insurance coverage and Health Insurance Portability and Accountability Act (HIPAA) regulations and policies related to telemedicine. The matter was immediately addressed and the U.S. administration on 17^th^March 2020 announced to loosen the regulations and lifted the constraints on telemedicine policies. As per the statement, the Medicare payments will be exempted for telehealth services (valid from 6^th^March 2020). Also, patients will be able to assess their doctors and consult them remotely through teleconferencing (phone, video conferences) at no extra cost. During this period of the COVID-19 crisis, physicians are now waived off the penalty for violating the HIPAA act, for using communications technologies, like FaceTime or Skype for discussing health issues with the patients.

Embarking on the clinical trials: Search for the COVID-19 vaccine and target antiviral therapy {#sec2-5}
----------------------------------------------------------------------------------------------

### NIH funded research on new antiviral agent, Remdesivir at Nebraska, Omaha {#sec3-1}

Remdesivir is an antiviral agent that has shown better activity than the antiretroviral agents like lopinavir and ritonavir. Unfortunately, remdesivir is not commercially available for clinical use and hence there is not much literature regarding its side effect profile and *in vivo* interactions with other drugs. Moving a step ahead, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) has initiated a clinical trial to test remdesivir for its clinical effectiveness at the University of Nebraska Medical Center (UNMC) in Omaha (*NCT04280705*)\[[Table 2](#T2){ref-type="table"}\].\[[@ref5]\]

###### 

Description of the Clinical trials currently actively running related to SARS-CoV-2 and COVID-19 Disease

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NCT No.       STATUS                    STUDY TITLE                                                                                                                         STUDY DESIGN                                         COUNTRY
  ------------- ------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------
  04308668      New, not yet recruiting   To test if post-exposure prophylaxis with hydroxychloroquine can prevent progression development of symptomatic\                    Study Type: Interventional\                          University of Minnesota Minneapolis, Minnesota,
                                          COVID19 disease after known exposure to the SARS-CoV2 virus.                                                                        Estimated Enrollment:1500 participants\              
                                                                                                                                                                              Allocation: Randomized\                              
                                                                                                                                                                              Intervention Model: Parallel Assignment\             
                                                                                                                                                                              Estimated Study Start Date: April 2020\              
                                                                                                                                                                              Estimated Study Completion Date: May 2021            

  04283461      Active, Recruiting        To study the Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection                       Study Type: Interventional\                          Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases Seattle, Washington
                                                                                                                                                                              Estimated Enrollment: 45 participants\               
                                                                                                                                                                              Allocation: Non-Randomized\                          
                                                                                                                                                                              Intervention Model: Sequential Assignment\           
                                                                                                                                                                              Actual Study Start Date: March 3, 2020\              
                                                                                                                                                                              Estimated Study Completion Date: June 1, 2021        

  04280705      Active, Recruiting        To study the Safety and Efficacy of Investigational\                                                                                Study Type: Interventional\                          Multicentric study, 50 sites globally, 17 centers in US
                                          Therapeutics for the Treatment of COVID-19 in Hospitalized Adults                                                                   Estimated Enrollment:394 participants\               
                                                                                                                                                                              Allocation: Randomized\                              
                                                                                                                                                                              Intervention Model: Parallel Assignment\             
                                                                                                                                                                              Actual Study Start Date: February 21, 2020\          
                                                                                                                                                                              Estimated Study Completion Date: April 2023          

  04292899      Active, Recruiting        To Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe Coronavirus Disease (COVID-19)   Study Type: Interventional\                          Multicentric study, US Centers: -Providence Regional Medical Center Everett Everett, Washington, -Swedish Center for Comprehensive Care Seattle, Washington,
                                                                                                                                                                              Estimated Enrollment:400 participants\               
                                                                                                                                                                              Allocation: Randomized\                              
                                                                                                                                                                              Intervention Model: Parallel Assignment\             
                                                                                                                                                                              Actual Study Start Date: March 6, 2020\              
                                                                                                                                                                              Estimated Study Completion Date: May 2020            

  NCT04329923   New, not yet recruiting   To Study Prevention And Treatment of COVID-19 with Hydroxychloroquine                                                               Study Type: Interventional\                          University of Pennsylvania Philadelphia, Pennsylvania, United States
                                                                                                                                                                              Estimated Enrollment: 400 participants\              
                                                                                                                                                                              Allocation:Randomized\                               
                                                                                                                                                                              Intervention Model:Parallel Assignment\              
                                                                                                                                                                              Estimated Study Start Date: April 6, 2020\           
                                                                                                                                                                              Estimated Study Completion Date: December 1, 2021    

  NCT04315298   Recruiting                Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19                                           Study Type: Interventional\                          -Multicentric Study\
                                                                                                                                                                              Estimated Enrollment:400 participants\               -54 Centers across U.S.
                                                                                                                                                                              Allocation:Randomized\                               
                                                                                                                                                                              Intervention Model:Parallel Assignment\              
                                                                                                                                                                              Actual Study Start Date: March 16, 2020\             
                                                                                                                                                                              Estimated Study Completion Date:March 16, 2021       

  NCT04328467   New, not yet recruiting   To determine if pre-exposure prophylaxis with hydroxychloroquine is effective for the prevention of COVID-19 disease.               Study Type: Interventional\                          University of Minnesota Minneapolis, Minnesota, United States
                                                                                                                                                                              Estimated Enrollment:3500 participants\              
                                                                                                                                                                              Allocation:Randomized\                               
                                                                                                                                                                              Intervention Model: Parallel Assignment\             
                                                                                                                                                                              Estimated Study Start Date: April 1, 2020\           
                                                                                                                                                                              Estimated Study Completion Date: August 2020         

  NCT04325672   New, not yet recruiting   Convalescent Plasma to Limit\                                                                                                       Study Type: Interventional\                          Mayo Clinic in Rochester Rochester, Minnesota, United States
                                          Coronavirus Associated\                                                                                                             Estimated Enrollment: 20 participants\               
                                          Complications: An Open Label, Phase 2A Study of High-Titer\                                                                         Intervention Model:Single Group\                     
                                          Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19                                                                       Assignment\                                          
                                                                                                                                                                              Estimated Study Start Date: April 1, 2020\           
                                                                                                                                                                              Estimated Study Completion Date: December 31, 2022   

  NCT04326452   Recruiting                Treating COVID-19 With a Bidirectional Oxygenation Valve                                                                            Study Type: Interventional\                          -TMC HealthCare Tucson, Arizona,\
                                                                                                                                                                              Estimated Enrollment :15 participants\               -Stanford University Stanford, California,\
                                                                                                                                                                              Intervention Model:Single Group\                     -Emory Saint Joseph's Hospital Atlanta, Georgia,
                                                                                                                                                                              Assignment\                                          
                                                                                                                                                                              Estimated Study Start Date: March 27, 2020\          
                                                                                                                                                                              Estimated Study Completion Date: June 1, 2020        

  NCT04311697   New, not yet recruiting   Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress (COVID-AIV)                                                Study Type: Interventional\                          -Research Center New York, New York, United States\
                                                                                                                                                                              Estimated Enrollment: 120 participants\              -Rambam Health Care Campus Haifa, Israel
                                                                                                                                                                              Allocation: Randomized\                              
                                                                                                                                                                              Intervention Model:Parallel Assignment\              
                                                                                                                                                                              Estimated Study Start Date: April 2020\              
                                                                                                                                                                              Estimated Study Completion Date: September 2020      

  NCT04329832   New, not yet recruiting   Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS)                          Study Type: Interventional\                          -Intermountain Medical Center Murray, Utah, United States\
                                                                                                                                                                              Estimated Enrollment:300 participants\               -University of Utah Salt Lake City, Utah, United States
                                                                                                                                                                              Allocation:Randomized\                               
                                                                                                                                                                              Intervention Model:Parallel Assignment\              
                                                                                                                                                                              Estimated Study Start Date: April 1, 2020\           
                                                                                                                                                                              Estimated Study Completion Date: December 31, 2021   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

(Adopted from <https://clinicaltrials.gov/ct2/results?cond=coronavirus.>)

### 1^st^ COVID-19 vaccine trial (mRNA-1273) at Seattle, Washington {#sec3-2}

Currently, there is no approved vaccine to prevent SARS-CoV-2 infection. On 16^th^ March 2020, NIAID launched a Phase 1 clinical trial (*NCT04283461*) to evaluate an investigational vaccine devised against COVID-19. It has begun at the Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. This is an open-label trial that aims to enroll 45 healthy adult volunteers ages 18 to 55 years over the next 6 weeks. Dr. Lisa A. Jackson, M.D., a senior investigator at KPWHRI is leading the trial. The investigational vaccine is called mRNA-1273 and has been built by the collaborative effort of NIAID scientists and biotechnology company Moderna, Inc., based in Cambridge, Massachusetts.\[[@ref6]\] The 45 participants will be grouped into 3 sets of 15 people in order to test different doses of the vaccine. Group 1, 2, and 3 will receive a dose of 25 micrograms (mcg), 100 mcg, and 250 mcg respectively in 2 sessions, 28 days apart. In total there will be 11 in-person and 4 phone visits over a 14-month period to capture the results.

### Convalescent sera as an option to contain COVID-19: A Johns Hopkins initiative, Baltimore {#sec3-3}

Scientists realize that there is still a long way to go before an anti-COVID-19 vaccine becomes a reality. Passive antibodies have successfully been used in patients exposed to hepatitis B and rabies viruses. Using this as a platform to work, Johns Hopkins immunologist, Dr. Arturo Casadevall proposed to use convalescent sera from COVID-19 recovered patients to treat individuals with early symptoms.\[[@ref7]\] This basically involves identifying recovered COVID-19 individuals with high titers of neutralizing antibodies. Serum from such individuals can be administered to high-risk populations like\[[@ref1]\] vulnerable individuals with comorbidities,\[[@ref2]\] health care providers, and\[[@ref3]\] individuals with exposure to confirmed cases. The possible risks involved with such therapy are immunological reactions like serum sickness, transfusion-related acute lung injury, and so on. The Johns Hopkins research team has released the funds to set up an operating facility at their center in Baltimore within the next few weeks. On similar lines, on 4^th^March 2020, Japan\'s one of the largest drug makers, Takeda Pharmaceuticals initiated a new program (TAK-888) to develop an anti-SARS-CoV-2 polyclonal hyperimmune globulin.

### Emergency use authorization of antimalarial drug for use in COVID-19 by FDA {#sec3-4}

Anti malarial drug, hydroxyl chloroquine (HCQ) has shown some anti-SARS-CoV activity *in vitro* studies. Following this, Gautret *et al*. found the combination of HCQ and azithromycin to be more effective than HCQ alone or standard care in their study group on COVID-19 patients in an open labelled study.\[[@ref8]\] Considering the limited options, the Food and Drug Administration (FDA) on 28^th^ March gave authorization for the emergency use of chloroquine phosphate and hydroxyl chloroquine sulfate for the treatment of COVID-19 patients when clinical trials are not available, or participation is not feasible. Many trials are already underway to confirm the efficacy of HCQ for COVID-19\[Link for upto date information: *<https://clinicaltrials.gov/>*. (NCT04329923, NCT04329832, NCT04318444)\].

Securing the borders: COVID-19 related International travel restrictions {#sec2-6}
------------------------------------------------------------------------

With the growing threat of COVID-19 pandemic, just like many other countries, on 11^th^ March 2020 the U.S.\'s Homeland Security suspended the entry of foreign nationals from Iran, China, and most of the European countries. Before as well, in January and February, a similar travel restriction was imposed on individuals who had been in China and Iran.

Overcoming the limited COVID-19 testing and insurance hurdle {#sec2-7}
------------------------------------------------------------

Currently, in the U.S., CDC is providing the COVID-19 test kits. CDC, in turn, procures these kits from the International Reagent Resource (IRR), a designated organization that acquires, authenticates, and produces these reagents. As of 16^th^ March 2020, in the U.S., approximately 25,162 specimens have already been tested. But still, a large gap between the demand and supply of COVID-19 testing kits have been felt. Considering the need of the hour, the FDA has already granted an emergency clearance to many biotechnical companies to commercialize their COVID-19 testing kits into the market for use by various tertiary and public community health centers. FDA aims for 1.4 million test kits to be accessible by next week, and approximately 5 million within a month. The US Congress also passed a bill on 13^th^ March 2020, which ensures a free access to COVID-19 testing, paid extension of sick leave for vulnerable, and provision of free food aid to the needy.

Tacking the economic downturn {#sec2-8}
-----------------------------

Worldwide, global markets are fluctuating due to the unstable economy and there is a fear of a recession even worse than 09/11. With mounting economic toll on Wall Street, New York, the US Treasury Secretary, Mr. Steven Mnuchin, in his press briefing said that the administration would consider for an \$850 billion stimulus proposal to shield the economic hit on business. Discussion is going on as well for a payroll tax cut for this year. The administration is also considering a \$50 billion economic relief package towards the airline industry. All these measures are being taken to ensure that the economy and trade do not suffer a huge loss and could survive in this time of crisis.

Predicting the Trajectory of COVID-19: US Preparedness and Strategy {#sec1-5}
===================================================================

Different countries have responded to the current pandemic with different strategies based on their previous experiences (example SARS pandemic, 2002-03), economic situation, health care infrastructure, and preparedness beforehand. Talking in the terms of numbers, apart from China, the other three countries who have successfully contained the further spread of COVID-19 are Hong Kong, Singapore, and South Korea. In contrast, European countries like France, Germany, and Spain, which were affected late, now all have more than 30--100 times more cases than the earlier mentioned countries. "Singapore Model" has shown that if acted early then the mortality can be minimized. Disease Outbreak Response System Condition (DORSCON) is a color-coded framework that Singapore follows when an infectious outbreak occurs, potential of the health hazard to its citizens. The framework has set general guidelines on what must be done in order to avoid and minimize the impact of infections. Countries like South Korea and China had to follow the "suppression model," which is basically doing a lockdown of the heavily inflicted cites thereby halting all daily activities, strict quarantine to homes for everyone unless medically needed. In contrast, by acting ahead of curve, Hong Kong and Singapore followed their suspected contacts, tested them liberally with strict quarantine if required, and sent strong and regular communication about social distancing and public awareness.

The U.S. has already entered into Stage III of the COVID-19 pandemic. We assume that the sky-high numbers of new COVID-19 cases being diagnosed daily across all the states of the U.S. is both due to the increased testing as well as community transmission. Till now U.S. administration is urging the public to keep following the social etiquettes, social distancing, and to stay in home as much as possible. Unlike countries like China, India, and Italy, the U.S. so far has not taken any stringent actions like a complete lockdown across all the states. With so many COVID-19 related deaths every day, the U.S is just behind Italy and Spain in terms of death toll. Hence, there is an ongoing debate of switching mode to suppression strategy from the current mitigation strategy. Few experts are vouching for a national-level lockdown order, with uniform measures across the whole country. Next few weeks are anticipated to be crucial for the U.S., as the scarcity of medical devices, lack of critical care beds, falling sick of health care professionals, and shortage of personal protective equipments have already plagued the health care infrastructure of many states like New York, New Jersey, etc., CDC, WHO, FDA and U.S administration are keeping an eye on the volatile COVID-19 situation and we hope to see some strict actions in near future to contain this COVID-19 pandemic.

Conclusion {#sec1-6}
==========

COVID-19 pandemic has caused enormous damage to the health, economy, trade, and finance sectors of the U.S. The current situation on COVID-19 is concerning and remains very fluid. The U.S. has always been a front runner when it comes to developing new medicines, vaccines, and diagnostics. Hopefully, the current ongoing trials on antiviral agents and vaccines will give us a new ray of hope soon. We appreciate the unwavering dedication of health care professionals and scientists towards their patients and the community during this health crisis.
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